Dianthus announces early GO decision in Phase 3 CAPTIVATE CIDP trial; reports FY2025 results

Dianthus Therapeutics, Inc. /DE/

Early GO decision: 20 confirmed responders with less than 40 participants; DSMB confirmed; no serious infections or discontinuations.
Plans to drop 600mg dose arm in Part B; enroll up to 256 patients (down from 480) to randomize 128 (down from 192).
FY2025 net loss $162.3M ($4.20/share) vs $85.0M ($2.55/share) in FY2024.
Cash $514.4M provides runway into 2028.
Phase 3 gMG trial of claseprubart to start mid-2026; top-line data expected 2H’28.

item 2.02item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.